Observational studyCanadian journal of gastroenterology & hepatology2025
Response to Proton-Pump Inhibitors Therapy in Pediatric Patients With Eosinophilic Esophagitis in Bogotá, Colombia.
Observational study in Canadian journal of gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Response to Proton-Pump Inhibitors Therapy in Pediatric Patients With Eosinophilic Esophagitis in Bogotá, Colombia.Canadian journal of gastroenterology & hepatology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease and a leading cause of food impaction in pediatric populations, with potential functional and structural complications. Proton-pump inhibitors (PPIs) are widely used as first-line therapy, but the response rate in Colombian children remains unknown. This study aimed to determine the initial histologic response to PPI therapy and describe clinical, endoscopic, and histological characteristics in a sample of pediatric patients with EoE from Bogotá, Colombia. Methodology: A retrospective observational longitudinal study of patients aged 2-18 years diagnosed with EoE at a tertiary care center between 2015 and 2022 was conducted. Patients underwent initial clinical and endoscopic assessment confirming esophageal eosinophilia (≥ 15 eosinophils per high-power field [eos/hpf]), followed by at least 8-week course of PPI therapy and a subsequent clinical-endoscopic re-evaluation. Treatment response was defined histologically as < 15 eos/hpf in follow-up esophageal biopsy. Demographic, clinical, endoscopic, and histological data were analyzed using descriptive and bivariate statistics. Results: We included 34 patients (median age 11 years; 61.8% boys). Sixteen (47%) achieved histological remission with initial PPI therapy. Being esomeprazole preferred in 88%, with median dose 1.37 mg/kg/day. No significant differences were observed between responders and nonresponders in demographic variables, familial and personal atopic history, symptoms, or endoscopic findings. Histologically, responders demonstrated significant reductions in eosinophil counts, as well as improvements in basal zone hyperplasia, eosinophilic abscesses, and eosinophil surface layering (all Discussion: This is the first study to assess PPI response in Colombian pediatric EoE patients, demonstrating a response rate consistent with existing literature. Histologic evaluation was identified as the most reliable marker of treatment success, underscoring the critical role of histopathological follow-up in this disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.